Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors by Pietarinen, Paavo O. et al.
Oncotarget22606www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 14), pp: 22606-22615
Differentiation status of primary chronic myeloid leukemia cells 
affects sensitivity to BCR-ABL1 inhibitors
Paavo O. Pietarinen1, Christopher A. Eide2,3, Pilar Ayuda-Durán4, Swapnil Potdar5, 
Heikki Kuusanmäki5, Emma I. Andersson1, John P. Mpindi5, Tea Pemovska5,6, Mika 
Kontro1, Caroline A. Heckman5, Olli Kallioniemi5, Krister Wennerberg5, Henrik 
Hjorth-Hansen7,8, Brian J. Druker2,3, Jorrit M. Enserink4, Jeffrey W. Tyner2,9, Satu 
Mustjoki1,10,*, Kimmo Porkka1,*
1Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital 
Comprehensive Cancer Center, Helsinki, Finland
2Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, 
OR, USA
3Howard Hughes Medical Institute, Portland, OR, USA
4Oslo University Hospital, University of Oslo, Oslo, Norway
5Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
6Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria
7Department of Hematology, St Olavs Hospital, Trondheim, Norway 
8Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 
Trondheim, Norway
9Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA
10Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland
*These authors contributed equally to this work
Correspondence to: Kimmo Porkka, email: Kimmo.porkka@helsinki.fi
Keywords: chronic myeloid leukemia, high-throughput drug screening, ex vivo, tyrosine kinase inhibitors, CD34
Received: September 20, 2016    Accepted: January 24, 2017    Published: February 07, 2017
ABSTRACT
Tyrosine kinase inhibitors (TKI) are the mainstay treatment of BCR-ABL1-
positive leukemia and virtually all patients with chronic myeloid leukemia in chronic 
phase (CP CML) respond to TKI therapy. However, there is limited information on the 
cellular mechanisms of response and particularly on the effect of cell differentiation 
state to TKI sensitivity in vivo and ex vivo/in vitro. We used multiple, independent 
high-throughput drug sensitivity and resistance testing platforms that collectively 
evaluated 295 oncology compounds to characterize ex vivo drug response profiles 
of primary cells freshly collected from newly-diagnosed patients with BCR-ABL1-
positive leukemia (n = 40) and healthy controls (n = 12). In contrast to the highly 
TKI-sensitive cells from blast phase CML and Philadelphia chromosome-positive acute 
lymphoblastic leukemia, primary CP CML cells were insensitive to TKI therapy ex vivo. 
Despite maintaining potent BCR-ABL1 inhibitory activity, ex vivo viability of cells was 
unaffected by TKIs. These findings were validated in two independent patient cohorts 
and analysis platforms. All CP CML patients under study responded to TKI therapy  
in vivo. When CP CML cells were sorted based on CD34 expression, the CD34-positive 
progenitor cells showed good sensitivity to TKIs, whereas the more mature CD34-
negative cells were markedly less sensitive. Thus in CP CML, TKIs predominantly 
target the progenitor cell population while the differentiated leukemic cells (mostly 
cells from granulocytic series) are insensitive to BCR-ABL1 inhibition. These findings 
have implications for drug discovery in CP CML and indicate a fundamental biological 
difference between CP CML and advanced forms of BCR-ABL1-positive leukemia.
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INTRODUCTION
All patients with chronic myeloid leukemia in 
chronic phase (CP CML) and other forms of BCR-
ABL1-positive leukemia are currently treated with 
BCR-ABL1 tyrosine kinase inhibitors (TKIs). CP CML 
patients experience a relatively normal life span and 
stay in remission for decades, some even after TKI 
discontinuation [1, 2]. However, not all patients respond 
optimally to TKIs and some develop intolerance or 
secondary resistance. Most cases of TKI resistance are 
caused by mutations in the kinase domain of the BCR-
ABL1 gene, but some patients develop resistance due to 
other mechanisms [3, 4]. Although third generation TKIs 
targeting key gatekeeper mutations have been developed 
(e.g. ponatinib), there still is a need for novel treatment 
modalities for suboptimal responders.
BCR-ABL1-positive leukemias are classified as 
CP CML, advanced phase CML, blast phase CML (BC 
CML) and Philadelphia chromosome-positive acute 
lymphoblastic leukemia (Ph+ ALL). Several biological and 
genetic factors are known to differentiate the BCR-ABL1-
positive leukemias but the basic mechanisms governing 
the evolution from chronic to blast phase are still mostly 
unknown [5]. On cell morphology level, CP CML cells 
consist mostly of differentiated, mature myeloid cells 
(predominantly neutrophils) with a short half-life, while 
in BC CML and Ph+ ALL the predominant population 
consists of undifferentiated, primitive blast cells.
We recently characterized drug responses in 
BC CML patient samples and cell lines using a high-
throughput drug sensitivity and resistance testing platform 
[6]. In this study we set out to examine drug responses 
in primary CP CML patient samples collected at the time 
of diagnosis with the aim of identifying new candidate 
drugs with efficacy against CP CML cells by BCR-ABL1 
dependent and independent mechanisms. 
RESULTS
Primary CP CML mononuclear cells are 
insensitive to TKI therapy ex vivo
We first assessed the ex vivo drug sensitivity of fresh 
primary bone marrow (BM) and peripheral blood (PB) 
mononuclear cells (MNCs) from 25 CP CML patients 
using a panel of 295 approved and investigational drugs. 
The ex vivo drug sensitivity was assessed with a sensitivity 
score taking into account the area under the dose-response 
curve and normalizing the value to drug responses 
observed in healthy controls (selective drug sensitivity 
score, sDSS). Primary CP CML MNCs (n = 10 BM and 
15 PB) were markedly less sensitive to TKIs and other 
drug classes ex vivo in comparison to BC CML (n = 5), 
Ph+ ALL (n = 3), and acute myeloid leukemia (AML, 
n = 20) patient samples (Figure 1). The sDSS values of 
ex vivo responses to the tested common TKIs are depicted 
in Figure 1. Most Ph+ ALL and BC CML carried the 
highly TKI-resistant gatekeeper T315I BCR-ABL1 kinase 
domain mutation, while all CP CML samples were BCR-
ABL1 wild type. Representative dose response curves 
for selected TKIs from individual CP CML, BC CML 
patient samples and CML cells lines are shown in Figure 2, 
illustrating almost complete lack of TKI sensitivity ex vivo in 
CP CML samples over a large TKI concentration range. We 
also tested the ex vivo drug sensitivity of CP CML samples 
Figure 1: Comparison of ex vivo leukemia-specific drug sensitivity scores (sDSS) of common TKIs in CP CML, BC 
CML, Ph+ ALL and AML samples. Colored symbols in BC CML and Ph+ALL graphs denote patients with TKI-resistant T315I (red) 
or E255K (blue) BCR-ABL1 kinase domain mutation. Lines denote the median sDSS of TKIs.
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using different culture conditions (e.g. different media 
or incubation times) and sample sources (bone marrow 
or peripheral blood), with little or no effect on the TKI 
sensitivities (Supplementary Figure 1). TKI sensitivities 
were low also when CP CML sample was tested with a 
cytotoxicity assay (CellTox Green, Promega) in parallel 
with standard cell viability assay (CellTiter-Glo, Promega) 
(Supplementary Figure 2). None of the CP CML patients 
under study showed primary hematological resistance 
to TKIs in vivo and all but one patient (CML CP 23) 
achieved at least a complete cytogenetic response at 
12 months of TKI therapy (Supplementary Table 1). Drug 
compliance was not formally assessed.
Lack of ex vivo/in vitro TKI sensitivity was 
independently confirmed from the Portland and Oslo sample 
cohorts using distinct but methodologically analogous drug 
sensitivity platforms. The Portland results showed that 
both the Ph+ ALL and BC CML samples were sensitive to 
BCR-ABL1 inhibitors ex vivo, whereas CP CML samples 
showed minimal sensitivity (Figure 3A). Data from the Oslo 
platform CP CML samples had very similar TKI sensitivity 
to healthy controls ex vivo (Figure 3B). 
Primary CP CML MNCs are relatively 
insensitive to other oncology drugs ex vivo
To gain further insight into the drug sensitivity 
profiles of CP CML MNCs, we assessed the sensitivity 
of CP CML MNCs to a broad range of drugs commonly 
used in hematology and oncology (list of drugs provided 
in Supplementary Table 2). Only 6 out of the 295 (2%) 
library compounds showed modest activity against CP 
CML MNCs ex vivo (average sDSS score > 5), while 
most drugs showed sensitivity that was closer to healthy 
control samples (Figure 4). The IGF-1R inhibitor BMS-
754807, mTOR inhibitor AZD8055, mitosis inhibitor 
paclitaxel, PI3K/mTOR inhibitor PF-04691502, EZH2 
inhibitor GSK343 and VEGFR inhibitor tivozanib showed 
moderate selectivity to CP CML in our drug testing panel 
(see Supplementary Figures 3 and 4). In contrast, MNCs 
from BC CML patients showed markedly better overall 
drug sensitivity compared to CP CML samples in direct 
comparisons (Figure 5). Clustering of the drug response 
profiles of patient samples included in this study revealed 
comparable drug sensitivity profiles between CP CML 
and healthy control samples with clear segregation from 
BC CML samples (Supplementary Figure 5). Hence, the 
observed drug insensitivies of CP CML MNCs ex vivo 
were not restricted to TKIs but were more global.
TKIs inhibit BCR-ABL1 signaling in primary 
CP CML MNCs
We next studied if the consistent lack of responses 
to TKIs in ex vivo drug testing was due to inability of 
TKIs to block cell signaling downstream of BCR-ABL1 
in primary CP CML MNCs. CRKL is a central tyrosine 
phosphorylated protein detected in cells of patients 
with CML, suggesting that its association with BCR-
ABL1 plays an important role in the pathogenesis of 
the disease. The specificity of CRKL phosphorylation to 
BCR-ABL1 signaling, partnered with the stability of the 
Figure 2: Individual ex vivo TKI dose-response curves in different types of CML cell samples. Shown are responses from 
TKI sensitive CML cell lines (K562, EM2), BC CML sample without TKI-resistant BCR-ABL1 mutations and typical CP CML samples 
from Cohort 1.
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Figure 3: Ex vivo TKI sensitivity testing data from Portland (A) and Oslo (B) validation cohorts and platforms. (A) Drug sensitivity 
score (DSS) was calculated for Portland samples and DSS of diagnose phase CP CML samples were compared with TKI-sensitive BC 
CML and Ph+ ALL samples. Tested concentration ranges were 13,72–10000 nM (imatinib and nilotinib) and 1,37–1000 nM (dasatinib and 
ponatinib). (B) TKI dose-response curves of CP CML (n = 3) and healthy BM (n = 3) samples were compared in Oslo platform.
Figure 4: Mean ex vivo drug testing results for BM samples from CP CML patients (red bars) and healthy controls 
(blue bars). Shown are the 50 most leukemia-specific drugs ranked by the selective drug sensitivity score (sDSS). Error bars denote 
standard deviation.
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phosphoprotein complex, has established this readout as 
a robust method to assess BCR-ABL1 status in primary 
cells and cell lines [7, 8]. We analyzed the effect of 
dasatinib treatment ex vivo on CRKL phosphorylation 
in three CP CML BM samples of unsorted MNCs using 
western blotting. Phosphorylation of the CRKL protein 
was completely inhibited by dasatinib at physiological 
concentrations in the CP CML MNCs (Figure 6). Thus, 
despite potent inhibition of BCR-ABL1 signaling in 
CP CML MNCs by TKIs ex vivo, the cellular viability 
remained unaffected, indicating that alternative pathways 
govern cellular viability and survival in CP CML MNCs.
Ex vivo TKI insensitivity is linked to cellular 
differentiation
In the primary BM and PB samples from CP CML 
patients used in this study, the vast majority of the BCR-
ABL1-positive MNCs were myelocytes, metamyelocytes 
and neutrophils. To assess whether there is a difference 
in ex vivo drug sensitivity between progenitor and mature 
cells, we sorted CP CML MNCs into CD34+ and CD34- 
fractions, and incubated the cells ex vivo with imatinib, 
dasatinib and ponatinib in similar drug testing conditions 
as performed previously. CD34+ CP CML MNCs were 
significantly more sensitive to TKIs than CD34- MNCs 
(Figure 7A), which was most pronounced with the more 
potent TKIs dasatinib and ponatinib.
We next assessed how dasatinib treatment ex vivo 
affects cell populations in unfractionated MNC samples 
by flow cytometric analysis. Although 72 h incubation 
by itself reduced the proportion of CD34+ cells in MNC 
samples, dasatinib treated wells had significantly lower 
numbers of CD34+ progenitor cells in comparison to 
control wells (p = 0.03, Figure 7B). CD34- cell proportion 
remained similar in both groups. Together these data 
indicate that the dependency of CML progenitor cells 
upon BCR-ABL1 activity is lost during differentiation into 
more mature cells.
DISCUSSION
BCR-ABL1-positive leukemias have been model 
diseases for the successful development of targeted, safe 
and efficacious cancer therapies. The advent of TKIs 
has dramatically changed the outcome of these diseases, 
in particular for patients with CP CML, many of whom 
currently have a normal life span [2]. However, cellular 
mechanisms of response and particularly the effect of cell 
differentiation state to TKI sensitivity in vivo and ex vivo/
in vitro have not previously been explored. 
We wanted to utilize the functional ex vivo drug 
testing platforms for discovering new therapies for CP 
CML patients, similar to our recent studies in BC CML in 
which we found several promising drug candidates [6]. We 
prospectively collected a cohort of 25 newly-diagnosed 
Figure 5: Comparison of overall ex vivo drug sensitivity of primary PB CP (A), BM CP (B) and BM BC CML (C) samples. Shown are 
the 50 most leukemia-specific drugs ranked by the averages of selective drug sensitivity score (sDSS). A selection of effective drug classes 
is highlighted with colors.
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CP CML patients and collected fresh primary PB and 
BM samples for a comprehensive ex vivo drug sensitivity 
assay platform testing 295 clinical oncology compounds 
at a broad 4-log concentration range for each sample [9]. 
Overall, primary MNCs from CP CML patients exhibited 
reduced sensitivity profiles to the tested drugs compared to 
our experience with acute leukemias or BC CML samples. 
Compounds targeting the PI3K/Akt/mTOR pathway had 
Figure 6: Ex vivo effect of dasatinib treatment on primary CP CML MNCs on BCR-ABL1 signaling as measured by 
phosphorylation of CRKL protein. Western blotting was performed on cell lysates before and after 24 h 100 nM dasatinib incubation. 
0.1% DMSO was used as a control treatment. CML cell line K562 and healthy BM MNC lysates were used as positive and negative 
controls, respectively.
Figure 7: Effect of cellular differentiation on ex vivo TKI sensitivity. (A) Primary BM CP CML MNC samples were sorted 
to CD34-positive and CD34-negative fractions and were incubated 72 h with imatinib, dasatinib and ponatinib. DSS score (see methods) 
was used as the viability readout. Lines denote median. (B) Unsorted CP CML MNC samples were incubated with 100 nM dasatinib or 
0.1% DMSO for 72 h. The CD34-positive and -negative cell percentages were analyzed with flow cytometry. Error bars denote standard 
deviation. ns, nonsignificant. 
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an effect on the viability of CP CML MNCs ex vivo, but 
the leukemia-specificity was modest. The IGF-1R inhibitor 
BMS-754807, PI3K/mTOR inhibitor PF-04691502 and 
mTOR inhibitor AZD8055 were the most effective in CP 
CML patient samples. Increased activity of the PI3K/Akt/
mTOR pathway has been proposed as an escape route for 
TKI resistance in BCR-ABL1-positive leukemias and 
combining nilotinib with dual PI3K/mTOR inhibitor has 
been shown to have a synergistic effect [10–12].
The most surprising finding in our study was the 
significant lack of efficacy of all clinically available ABL 
TKIs on CP CML MNCs ex vivo. We systematically 
ruled out any technical cause for the insensitivity (e.g. 
tested different culture media, sample sources, incubation 
times and conditions, read-outs, concentrations of cells 
and compounds). Importantly, identical experimental 
conditions have resulted in good and clinically meaningful 
drug sensitivities in primary samples from a variety of 
chronic and acute hematological malignancies we have 
tested. Samples from patients with BC CML and non-
mutated Ph+ ALL were highly sensitive to TKIs ex vivo. 
The results on CP CML MNCs were further validated 
in two independent patient cohorts and analogous drug 
testing platforms with the same result: TKIs had minimal 
effects on the viability of primary CP CML MNCs ex vivo. 
Strikingly, all CP CML patients of the current study cohort 
responded well to TKI therapy in vivo, with all but one 
patient achieving at least a complete cytogenetic response.
We next tested if TKIs inhibited the BCR-ABL1 
signaling pathway in CP CML MNCs ex vivo. We showed 
that dasatinib potently inhibited CRKL phosphorylation 
in these cells ex vivo. Thus, CP CML MNC viability 
remained unaffected despite efficient inhibition of the 
canonical BCR-ABL1 signaling by TKIs.
As the MNC samples from diagnostic-phase CP 
CML patients are composed mostly of myelocytes and 
other cells from granulocytic series we tested if there was 
difference in ex vivo TKI responses between immature and 
mature MNCs. By cell sorting experiments, we observed 
that TKIs were clearly more effective in CD34+ progenitor 
cell fraction as compared to the more mature CD34- 
population. Incubation with dasatinib also efficiently 
decreased the numbers of CD34+ cells, but had little effect 
on the numbers of cells in the CD34- fraction. Thus in 
CP CML, the effect of TKIs is derived from targeting the 
progenitor cell population while the bulk of mature cells 
with little or no proliferative potential are insensitive to 
BCR-ABL1 inhibition. However, due to the short half-
life of mature myeloid cells, they are eliminated within 
2 weeks after the TKI-driven eradication of progenitor 
cells. This may explain the relatively more rapid initial 
responses seen in patients with BC CML and Ph+ALL as 
compared to CP CML patients.
Over the past decade, hundreds of studies have 
examined the sensitivity of drugs on BCR-ABL1-
positive leukemic cells in vitro or ex vivo. However, the 
vast majority has been performed on immortalized cell 
lines, which are derived from and reflect characteristics 
of advanced BCR-ABL1-positive leukemias (e.g. the BC 
CML-derived K562 cell line) or on long-term colony 
assays involving significant modifications for modelling 
the BM microenvironment [13–15]. In contrast, only a few 
studies have been performed on primary MNCs collected 
from CP CML patients. A few studies with imatinib have 
shown that blocking of BCR-ABL1 signaling induce 
growth inhibition more effectively in the earlier stages of 
CML cell maturation [16, 17]. Our study confirms these 
results and shows that this phenomenon is not limited to 
only imatinib but applies to other TKIs as well. 
Key question for future studies is the isolation of 
molecular switches governing the differentiation-induced 
changes in TKI sensitivity from highly TKI-sensitive 
BCR-ABL1-positive blast-level cells to completely 
insensitive mature myeloid cells, which comprise the 
bulk of disease burden in CP CML. If these switches are 
druggable molecules, we might have a new therapeutic 
tool for transforming CML blast cells to mature 
neutrophils which will have a very short life span in vivo, 
similar to differentiation induced by all-trans retinoic acid 
in acute promyelocytic leukemia.
To conclude, we observed low levels of ex vivo 
drug sensitivity in primary CP CML samples when 
compared to samples from advanced BCR-ABL1-positive 
leukemia. Most importantly, CP CML MNC samples 
showed minimal sensitivity to BCR-ABL1 TKIs ex vivo 
reflecting a differential sensitivity among progenitor and 
mature CML cells. Our findings have implications for 
drug discovery in CP CML in achieving treatment-free 
remission and indicate a fundamental biological difference 
between CP CML and advanced forms of BCR-ABL1-
positive leukemia.
MATERIALS AND METHODS
Study cohorts and samples
Patient samples used in this study were derived from 
3 independent cohorts. Cohort 1 (Helsinki) was the main 
study cohort and Cohorts 2 (Portland) and 3 (Oslo) served 
as validation cohorts.
Cohort 1 (Helsinki) consisted of diagnostic phase 
samples collected from 25 CP CML patients (15 PB, 
10 BM samples), 5 patients BC CML (4 BM, 1 PB), 3 
patients Ph+ ALL (BM) and from 20 patients with AML 
(18 BM, 2 PB). BM samples from 9 healthy donors were 
used as controls. Cohort 1 included diagnostic phase 
samples from patients participating in the Nordic CML 
Study Group Clinical first-line study on the combination 
of pegylated interferon-α2b and dasatinib [18] and were 
diagnosed, sampled and treated at the corresponding 
Nordic clinical study centers. The samples were analyzed 
at the Hematology Research Unit Helsinki and the Institute 
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for Molecular Medicine Finland, University of Helsinki, 
Finland.
Cohort 2 (Portland) consisted of diagnostic phase 
samples collected from 2 CML patients in CP and from 
1 patient in BC, and from 1 patient with Ph+ ALL (all 
samples from BM). Cohort 2 patients were diagnosed, 
sampled, and treated and had samples analyzed at the 
Division of Hematology and Medical Oncology, Knight 
Cancer Institute, Oregon Health & Science University, 
Portland, OR, USA. All samples were collected under 
informed consent using a protocol approved by the Oregon 
Health & Science University Institutional Review Board.
Cohort 3 (Oslo) consisted of BM samples collected 
from 3 diagnostic phase CML patients and 3 BM samples 
from healthy controls. Cohort 3 patients were diagnosed, 
sampled and treated at the Department of Hematology, 
Oslo University Hospital, Norway, and analyzed at the 
Department of Microbiology at Oslo University Hospital 
All samples were collected after obtaining written 
informed consent (HRUHLAB2, permit numbers 
239/13/03/00/2010, 303/13/03/01/2011, Helsinki 
University Hospital Ethics Committee). The study was 
approved by respective local ethical review boards in 
accordance with the Declaration of Helsinki. MNCs were 
separated from BM aspirates or PB samples by density 
gradient centrifugation.
Ex vivo drug sensitivity testing
Cohort 1 (Helsinki)
The drug sensitivity and resistance testing (DSRT) 
protocol used for Cohort 1 samples has been described 
previously [6, 9]. The drug collection contained 295 
different compounds and covered most U.S. Food and 
Drug Administration/European Medicines Agency (FDA/
EMA)-approved anticancer drugs, as well as emerging 
investigational and preclinical compounds covering a wide 
range of molecular targets (Supplementary Table 2). The 
compounds were obtained from the National Cancer Institute 
Drug Testing Program (NCI DTP) and commercial chemical 
vendors. Drugs were pre-plated in 384-well plates in 5 
different concentrations covering a 10,000-fold concentration 
range and primary cells added at 10,000 cells per well. All 
plates were incubated in a humidified environment at 37°C 
and 5% CO2 for 72 h. Cell viability was measured using 
the CellTiter-Glo luminescent assay (Promega, Madison, 
WI, US) according to the manufacturer’s instructions with 
a PHERAstar FS (BMG Labtech, Ortenberg, Germany) 
plate reader. Dose response curves were generated based 
on the viability readouts and a drug sensitivity score (DSS) 
was calculated [19]. DSS is an integrative and robust drug 
response metric based on normalized area under the curve 
by taking into account all four curve fitting parameters. 
DSS values were further normalized against the median 
values from healthy controls (healthy BM MNCs) to obtain 
a selective DSS (sDSS), which was then used to measure 
leukemia-specific drug sensitivity for DSRT results. Drugs 
with sDSS values > 5 were considered effectively selective 
and > 10 highly selective to tested cells.
Cohort 2 (Portland)
The ex vivo drug testing platform used for Cohort 
2 samples platform was performed using a modification 
of a protocol described previously [20]. Briefly, 10,000 
cells per well were seeded into pre-drugged 384-well 
plates containing 8-point dose response curves of each 
drug spanning a ~1000-fold concentration range over 
3-fold serial dilutions. Cells were then incubated for 
72 h at 37°C and 5% CO2. After incubation, cells were 
subjected to a CellTiter 96 AQueous One solution-based 
cell proliferation assay (Promega, Madison, WI, USA) and 
read on a BioTek Synergy 2 plate reader. 
Cohort 3 (Oslo)
Samples were analyzed as described for Cohort 
1, except that the Selleck anticancer library was used for 
ex vivo drug sensitivity screening.
In order to convert the ex vivo drug testing data from 
all 3 platforms used in this study to a common metric, raw 
sensitivity scores from all samples were analyzed with the 
same bioinformatics pipeline developed at the Institute 
for Molecular Medicine Finland [19]. The resulting 
DSS scores are comparable when analyzing samples 
within each cohort, but not between cohorts due to small 
variations in analysis conditions (e.g. viability assays, drug 
concentration ranges, cell culture media). 
Progenitor cell isolation
To test differences in drug sensitivities between 
immature and mature CML cell populations, BM MNCs 
from five Cohort 1 CP CML patient samples were sorted 
into CD34+ and CD34- fractions using an AutoMACS 
Separator (Miltenyi Biotec, Bergisch Gladbach, Germany). 
CD34+ and CD34- cells were seeded in separate groups 
into predrugged plates containing imatinib, dasatinib and 
ponatinib. Identical drug sensitivity assay and analysis 
conditions were used as described above for Cohort 1.
Flow cytometry analysis
We analyzed the CD34+ cell populations from 
unsorted BM MNCs of four CP CML patient samples 
by flow cytometry using a FACSVerse instrument (BD 
Biosciences, San Jose, CA, USA). MNCs were stained 
with a FITC labeled CD34 antibodiy (BD Biosciences). A 
total of 2 × 106 cells per well were seeded in 24-well plates 
at a density of 1 × 106 cells/ml. Plates were incubated 
72 h in the presence of 100 nM dasatinib or 0.1% dimethyl 
sulfoxide (DMSO) (vol/vol) dissolved in Mononuclear 
Cell Medium (MCM, PromoCell, Heidelberg, Germany). 
Sample analysis was done before and after the incubation 
using the FlowJo software (FlowJo, LCC, Ashland, 
OR, USA).
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Western blot analysis
Unsorted BM MNCs from 3 CP CML patient 
samples were seeded in 6-well plates (3 × 106 per well) 
in MCM and lysed in RIPA buffer before and after 24 h 
incubation with 100 nM dasatinib or 0.1% DMSO. Protein 
lysates from the CML cell line K562 and from a healthy 
volunteer (BM) were used as positive and negative 
controls, respectively. The protein lysates were loaded to 
12% SDS-polyacrylamide gel (Bio-Rad, Hercules, CA, 
USA). The proteins were transferred to a nitrocellulose 
membrane (Bio-Rad), after which the membrane was 
blocked with 5% bovine serum albumin (BSA) for 1 h. 
Primary phospho-CRKL antibody (Cell Signaling 
Technologies, MA, USA) was diluted 1:500 to phosphate-
buffered saline + 0,05% Tween 20 (PBS-T) + 5% BSA 
and incubated with the membrane for 1 hour at RT. 
Secondary infrared 800CW anti-rabbit antibody (LI-COR 
Biosciences, NE, USA) was diluted 1:15 000 to PBS-T + 
5% BSA and incubated with the membrane for 1 h. Total 
CRKL was measured from the same membrane afterwards 
with primary CRKL antibody (Santa Cruz, Dallas, TX, 
USA, 1:1 000)  and visualized with the same secondary 
800CW antibody. The Odyssey imaging system (LI-COR 
Biosciences) was used to visualize proteins. 100 nM 
dasatinib was used for western blot and flow cytometry 
experiments since this concentration is nearest the average 
physiological concentration in plasma [21].
Statistical analysis
The non-parametric Spearman’s rank correlation 
coefficient was calculated with SPSS Statistics software 
(version 22, IBM, Armonk, NY, USA). All correlation 
analyses were performed using DSS profiles of the primary 
patient cell samples. Clustering of the drug sensitivity 
profiles across patient samples was performed using 
unsupervised hierarchical complete-linkage clustering 
using Spearman and Euclidean distance measures of the 
drug and sample profiles, respectively. Clustering analyses 
were performed using sDSS profiles of the patient samples 
from cohort 1. Mann-Whitney U test was performed to 
study the difference between two groups. P-values below 
0.05 were considered significant.
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